Live Markets
Wednesday, July 29, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
Markets · Healthcare

AccuStem Sciences, Inc. (ACUT)

OQB · Biotechnology

$0.220.00 (0.00%)Quote refreshed

Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires

Market Cap
$3.5M
P/E (TTM)
EPS
$-0.12
Div Yield
52W Range
$0.16–$2.33
Beta
1.88

Company overview

AccuStem Sciences, Inc., a clinical stage diagnostics company, focuses on developing and commercializing a suite of novel genomic tests for oncology care. The company offers MSC test, a 24-micro RNA (miRNA) assay designed to help determine whether lung nodules identified by low dose computer tomography screening are benign or malignant. It also provides StemPrintER, a 20-gene prognostic assay to predict the risk of distant recurrence in luminal breast cancer patients. AccuStem Sciences, Inc. was founded in 2013 and is headquartered in New York, New York.

4 employeesaccustem.com

Peers in Healthcare

AccuStem Sciences, Inc. has no peer companies in this window.

Recent press releases

AccuStem Sciences, Inc. has not issued a press release in this window.

SEC filings

All filings →

AccuStem Sciences, Inc. has not filed an SEC document in this window.

AccuStem Sciences, Inc. has no reported insider trades in the last 90 days.

Institutional holders

All holders →
As of 2024-12-31

People at AccuStem Sciences, Inc.

All people →

Quarterly financials

Full financials →
Revenue trend
03/25
NI -$440.4K
06/25
NI -$401.4K
09/25
NI -$399.9K
RevenueNI = Net Income
EPS trend (diluted)
Latest: $-0.02
Prior: $-0.02
Revenue sparkline
ACUT (OQB) Stock Quote, Press Releases & SEC... | Cayman Journal | Cayman Journal